Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Yanlin Song, Zhenfei Bi, Yu Liu, et al.
Genes & Diseases (2022) Vol. 10, Iss. 1, pp. 76-88
Open Access | Times Cited: 109
Dynamic regulation of RAS and RAS signaling
Walter Kölch, Dénes Berta, Edina Rosta
Biochemical Journal (2023) Vol. 480, Iss. 1, pp. 1-23
Open Access | Times Cited: 53
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance
Damien Reita, L. Pabst, Erwan Pencreach, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1321-1321
Open Access | Times Cited: 60
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zining Zhang, Heng Zhang, Xiang Liao, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 28
Targeting the RAS upstream and downstream signaling pathway for Cancer treatment
Md. Arafat Hossain
European Journal of Pharmacology (2024) Vol. 979, pp. 176727-176727
Closed Access | Times Cited: 13
Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors
Marcell Baranyi, Eszter Molnár, Luca Hegedűs, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 6, pp. 1059-1072
Open Access | Times Cited: 12
Targeting paraptosis in cancer: opportunities and challenges
Fangquan Chen, Hu Tang, Xiutao Cai, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 3, pp. 349-363
Open Access | Times Cited: 11
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
Leonard J. Ash, Ottavia Busia-Bourdain, Daniel Okpattah, et al.
Current Oncology (2024) Vol. 31, Iss. 4, pp. 2024-2046
Open Access | Times Cited: 10
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Resistance looms for KRAS G12C inhibitors and rational tackling strategies
Junmin Zhang, Jilei Zhang, Qing Liu, et al.
Pharmacology & Therapeutics (2021) Vol. 229, pp. 108050-108050
Closed Access | Times Cited: 44
Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer
Song Wu, Ruilin Pan, Jibu Lu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 29
Glimmers of hope for targeting oncogenic KRAS-G12D
Daolin Tang, Rui Kang
Cancer Gene Therapy (2022)
Open Access | Times Cited: 29
Coumarin derivatives with potential anticancer and antibacterial activity: Design, synthesis, VEGFR‐2 and DNA gyrase inhibition, and in silico studies
Soha H. Emam, Rasha A. Hassan, Eman O. Osman, et al.
Drug Development Research (2023) Vol. 84, Iss. 3, pp. 475-499
Closed Access | Times Cited: 17
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3641-3649
Open Access | Times Cited: 16
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways
Koushik Mondal, Mahesh Kumar Posa, Revathi P Shenoy, et al.
Cells (2024) Vol. 13, Iss. 14, pp. 1221-1221
Open Access | Times Cited: 6
Novel Inhibitor-Based Therapies for Thyroid Cancer—An Update
Maciej Ratajczak, Damian Gaweł, Marlena Godlewska
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11829-11829
Open Access | Times Cited: 36
KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
Zheng Gao, Jiafeng Chen, Xiaogang Li, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
Olamide Tosin Olaoba, Temitope Isaac Adelusi, Ming Yang, et al.
Cancers (2024) Vol. 16, Iss. 10, pp. 1808-1808
Open Access | Times Cited: 5
Study on the Synergistic Effect of Klotho and KRAS on Reducing Ferroptosis After Myocardial Infarction by Regulating RAP1/ERK Signaling Pathway
Cheng-Zhe Cai, Yangjie Wu, Xiaoqian Feng, et al.
Applied Biochemistry and Biotechnology (2025)
Closed Access
The Persistent Power of the Taxane/Platin Chemotherapy
Lucy B. Xu, Elizabeth R. Smith, Vasili Koutouratsas, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1208-1208
Open Access
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia
Alejandro M. Hortal, Clara L. Oeste, Claudia Cifuentes, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 20
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Pharmacokinetics, Bioavailability, and Tissue Distribution of the Kirsten Rat Sarcoma Inhibitor Adagrasib in Rats Using UPLC-MS/MS
Lei Pan, Wanying Shen, Huijuan Tang, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 1-12
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top